Leqvio, a medication used to lower cholesterol, generated $1.7 billion in sales in 2023 [1]. Novartis, the pharmaceutical company that markets Leqvio, reported that the drug achieved this revenue primarily through prescription growth [1].
How is Leqvio’s Revenue Performing Quarter-Over-Quarter?
In the fourth quarter of 2023, Leqvio's sales reached $483 million [1]. This reflects a significant increase compared to the same period in the previous year. The company attributed this growth to strong performance in key markets and an expanding patient base [1].
What Are Leqvio's Upcoming Patent Expirations?
Leqvio, known generically as inclisiran, has several patents protecting its market exclusivity. According to DrugPatentWatch.com, the earliest anticipated patent expiry date for Leqvio is in 2027, with further patents extending protection into 2034 and beyond [2]. These patent dates are crucial for understanding when generic versions of the drug might become available.
Who Are Leqvio's Main Competitors?
Leqvio competes in the cholesterol-lowering market with several other drug classes and specific medications. These include statins, PCSK9 inhibitors like Praluent and Repatha, and ezetimibe [3]. The market is highly competitive, with new therapies continually emerging.
What is the Mechanism of Action for Leqvio?
Leqvio works by targeting and silencing the synthesis of PCSK9 (proprotein convertase subtilisin/kexin type 9) in the liver [4]. PCSK9 is a protein that reduces the number of LDL receptors on the liver, thereby increasing LDL cholesterol levels. By inhibiting PCSK9, Leqvio increases the number of LDL receptors available to clear LDL cholesterol from the blood, leading to a significant reduction in LDL-C [4]. This is a different approach compared to statins, which primarily inhibit cholesterol synthesis in the liver.
What Clinical Data Supports Leqvio's Efficacy?
Leqvio's efficacy has been demonstrated in clinical trials, notably the ORION program [4]. These studies showed that Leqvio significantly reduced LDL cholesterol levels in patients with hypercholesterolemia, including those at high cardiovascular risk [4]. The drug is administered via subcutaneous injection every six months after an initial loading dose [4].
What Are the Potential Risks or Side Effects of Leqvio?
Common side effects reported for Leqvio include injection site reactions, such as pain, redness, or itching [3]. Other reported side effects can include nasopharyngitis, upper respiratory tract infection, and influenza [3]. The long-term safety profile is continually being assessed through ongoing clinical monitoring [4].
Sources:
[1] https://www.novartis.com/news/media-releases/novartis-announces-fourth-quarter-and-full-year-2023-results
[2] https://drugpatentwatch.com/
[3] https://www. Drugs.com/lekvio.html
[4] https://www.us.Leqvio.com/